Capital World Investors
OCUL icon

Capital World Investors’s Ocular Therapeutix OCUL Stock Holding History

Capital World Investors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-2,028,000
Closed -$19.6M – 510
2016
Q1 		$19.6M Hold
2,028,000
– – 0.01% 405
2015
Q4 		$19M Hold
2,028,000
– – 0.01% 428
2015
Q3 		$28.5M Hold
2,028,000
– – 0.01% 392
2015
Q2 		$42.6M Buy
2,028,000
+1,229,271
+154% +$30.5M 0.01% 381
2015
Q1 		$33.5M Buy
+798,729
New +$26.3M 0.01% 398

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGCM
Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

Capital World Investors's OCUL Position: Q2 2016 in Review

Capital World Investors sold out of Ocular Therapeutix (OCUL) in Q2 2016, closing a stake of 2,028,000 shares — an estimated $19.6M sold.

Capital World Investors first reported a position in OCUL in Q1 2015 and held it in 5 quarters. The position peaked at $42.6M in Q2 2015. 75 funds tracked by Wall St. Rank hold OCUL as of Q2 2016.

  • Capital World Investors reported no remaining Ocular Therapeutix position as of Q2 2016 after selling out during the quarter.
  • Capital World Investors sold 2,028,000 Ocular Therapeutix shares in Q2 2016, an estimated $19.6M.
  • Capital World Investors first reported a position in Ocular Therapeutix in Q1 2015 and held it in 5 quarters.
  • Capital World Investors's Ocular Therapeutix position peaked at $42.6M in Q2 2015.
  • 75 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2016.

Based on Capital World Investors's 13F filing for Q2 2016, filed 15 Aug 2016.